In a preclinical assessment of 16 dipyridamole analogues, VK 774 was identified as the most potent agent for modifying platelet behavior and antithrombotic action, though no clear structure-activity relationship was found.
VK 774 merits further preclinical testing as lead antithrombotic analogue; leaves open structure-activity relationships for clinical translation.
Sixteen analogues of dipyridamole have been examined for their effectiveness in modifying ADP— and noradrenaline-induced aggregation and electrophoretic mobility change, and for their antithrombotic action in injured rabbit arteries. No clear relationship has been demonstrated between the potency of the analogues in modifying the three test systems and no correlation could be shown between the chemical configuration of the analogues and their activity. VK 774 is the most potent analogue so far examined.
No takes yet. Share an insight, caveat, or question.
Hampton et al. (1972) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: